UY38711A - Formas en estado sólido - Google Patents

Formas en estado sólido

Info

Publication number
UY38711A
UY38711A UY0001038711A UY38711A UY38711A UY 38711 A UY38711 A UY 38711A UY 0001038711 A UY0001038711 A UY 0001038711A UY 38711 A UY38711 A UY 38711A UY 38711 A UY38711 A UY 38711A
Authority
UY
Uruguay
Prior art keywords
solid state
state forms
fluoro
methyl
salt
Prior art date
Application number
UY0001038711A
Other languages
English (en)
Inventor
Stephan D Parent
Mary Chaves
Ron C Kelly
Prashant Agarwal
Darren Leonard Reid
Roman Shimanovich
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY38711A publication Critical patent/UY38711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona una forma cristalina y sales estables de 6-fluoro-7-(2-fluoro-6-hidroxifenil)-1-(4-metil-2-(2-propanil)-3-piridinil)-4-((2S)-2-metil-4-(2-propenoil)-1-piperazinil)pirido[2,3-d]pirimidin-2(1H)-ona, incluyendo varias formas de sal clorhidrato, una forma de sal fosfato, una forma de sal mesilato, y formas en estado sólido de las mismas, composiciones farmacéuticas y métodos de tratamiento de una enfermedad mediada por la inhibición de KRAS G12C.
UY0001038711A 2019-05-21 2020-05-21 Formas en estado sólido UY38711A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962851049P 2019-05-21 2019-05-21

Publications (1)

Publication Number Publication Date
UY38711A true UY38711A (es) 2020-11-30

Family

ID=71016701

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038711A UY38711A (es) 2019-05-21 2020-05-21 Formas en estado sólido

Country Status (10)

Country Link
US (1) US20220235045A1 (es)
EP (1) EP3972972A1 (es)
JP (1) JP2022532790A (es)
AR (1) AR119741A1 (es)
AU (1) AU2020277398A1 (es)
CA (1) CA3140394A1 (es)
MX (1) MX2021014235A (es)
TW (1) TW202110836A (es)
UY (1) UY38711A (es)
WO (1) WO2020236948A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102592246B1 (ko) 2016-12-22 2023-10-23 암젠 인크 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP4141005B1 (en) 2017-09-08 2024-04-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
MA52496A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3790551A4 (en) 2018-05-07 2022-03-09 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3883565A1 (en) 2018-11-19 2021-09-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
US20230183235A1 (en) * 2020-05-20 2023-06-15 Teva Pharmaceuticals International Gmbh Solid state forms of amg-510 and process for preparation thereof
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
TW202229278A (zh) * 2020-11-26 2022-08-01 大陸商上海翰森生物醫藥科技有限公司 含氮雜環類衍生物的鹽、晶型及其製備方法和應用
WO2022246069A1 (en) 2021-05-19 2022-11-24 Teva Pharmaceuticals International Gmbh Process for preparation of sotorasib and solid state form thereof
CN114605406B (zh) * 2021-09-18 2023-05-26 都创(上海)医药开发有限公司 Amg510化合物的晶型及其制备方法和用途
CN115368358A (zh) * 2022-09-01 2022-11-22 浙江九洲药业股份有限公司 一种Sotorasib新晶型及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP4141005B1 (en) * 2017-09-08 2024-04-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same

Also Published As

Publication number Publication date
MX2021014235A (es) 2022-03-11
AU2020277398A1 (en) 2021-12-09
EP3972972A1 (en) 2022-03-30
US20220235045A1 (en) 2022-07-28
JP2022532790A (ja) 2022-07-19
CA3140394A1 (en) 2020-11-26
TW202110836A (zh) 2021-03-16
WO2020236948A1 (en) 2020-11-26
AR119741A1 (es) 2022-01-05

Similar Documents

Publication Publication Date Title
UY38711A (es) Formas en estado sólido
UY38710A (es) Formas en estado sólido
PE20211411A1 (es) Compuestos de anillo fusionado
PH12019500776A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2020011250A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CY1122046T1 (el) Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
CY1123025T1 (el) Αναστολεις βρωμοεπικρατειας
MX2022000826A (es) Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton.
EA201890888A1 (ru) Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53
MY195669A (en) 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1 -Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer
NZ726042A (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2016065028A8 (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
EP4275754A3 (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
RU2021102805A (ru) 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
AR035573A1 (es) Profarmacos de pirimidinas inhibitorias de la replicacion de hiv
BRPI0813695B8 (pt) compostos de heteroaril piridil e fenil benzenossulfonamidas fundidas, composição, método de modular a função de ccr2, usos dos compostos e forma cristalina
UY29198A1 (es) Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
PL3357922T3 (pl) Pochodne 2-((5-(1-(3-(metylosulfonylo)propylo)piperydyn-4-ylo)pirydyn-2-ylo)amino)pirydo[2,3-d]pirymidyn-7(8h)-onu i związki pokrewne jako inhibitory cdk4 do leczenia nowotworów
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
TN2017000158A1 (en) Carbazole derivatives
SG10201810057UA (en) Crystalline fgfr4 inhibitor compound and uses thereof
CA3016830C (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
CY1123527T1 (el) Αντιφυματικος παραγοντας
PH12019502830A1 (en) Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof